Top 20 Companies in the Global Cardiotonic Agents Market: Global Share, Market Size, Revenue Report (2024–2035)
RELEASE DATE: Mar 2026 Author: Spherical InsightsRequest Free Sample Speak to Analyst
Introduction
Cardiovascular diseases (CVDs) have emerged as the main cause of disabilities and deaths worldwide. Heart failure is one of the most common forms of cardiovascular disease. Globally, around 17.8-19.8 million people die each year due to CVDs, accounting for 32% death globally. The upcoming years promise to witness a rise in the number of heart failures caused by an increase in the ageing population and the incidence of obesity and diabetes and high blood pressure. The increased incidence of this condition has created a greater need for cardiotonic medications, which physicians use to treat patients. Researchers are currently developing multiple medications that aim to minimise the chances of cardiovascular-related fatalities.
The progress of the market for cardiotonic agents receives its impetus from technological innovations which enable the creation of new cardiotonic products. Scientists are currently developing new medications that will provide better treatment results and greater patient safety than existing therapies. Novartis created Entresto as a combination medication that successfully lowers both cardiovascular mortality rates and hospital admissions caused by heart failure. Pharmaceutical companies allocate their resources toward developing new medications while also focusing on creating modern drug delivery systems and innovative medicine delivery methods. Total global pharma R&D investment is over USD 276-USD 288 Billion annually. Large pharma companies invest 30-34 percent of their revenue in R&D, reflecting high focus on innovation.
Navigate Future Markets with Confidence: Insights from Spherical Insights LLP
The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of The Cardiotonic Agents Market
Cardiotonic Agents Market Size & Statistics
- The Market Size for Cardiotonic Agents Was Estimated to be worth USD 2.9 Billion in 2024.
- The Market Size is Going to Expand at a CAGR of 12.5% between 2025 and 2035.
- The Global Cardiotonic Agents Market Size is anticipated to reach USD 10.59 Billion by 2035.
- North America is estimated to dominate the market during the forecast period in the Cardiotonic Agents Market.
- Asia-Pacific is projected to grow the fastest during the forecast period in the Cardiotonic Agents Market.
Market Segmentation
Global Cardiotonic Agents Market Size, Share, By Drug Type (Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents, and Others), By Application (Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension, and Others), By Route of Administration (Oral and Parenteral), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035.
Regional growth and demand
North America is expected to dominate the market during the forecast period in the cardiotonic agents market.
North America held the majority of the market share by revenue for the cardiotonic agents market. This dominance is because the region experiences high rates of cardiovascular diseases, which require advanced healthcare facilities and increased healthcare spending. The U.S. represents the largest market for cardiotonic agents within North America because multiple major pharmaceutical companies operate throughout the area. The companies that operate in this market include Pfizer Inc, Novartis, and Amgen. The companies in this industry work to develop new cardiotonic agents, which they will bring to market.
Asia-Pacific is projected to grow the fastest during the forecast period in the cardiotonic agents market.
Asia-Pacific is projected to grow the fastest during the forecast period in the cardiotonic agents market. The first two components that drive the growth of the cardiotonic agents market in the region stem from the rising cardiovascular disease rates and the increasing need for efficient medical solutions. The demand for cardiotonic agents in the Asia-Pacific markets has increased because of the growing elderly population in that area. The pharmaceutical market in the Asia Pacific countries expands because major companies operate in Japan, China, and India.
Ready to lead the Cardiotonic Agents Market ?
Discover the regional trends and growth factors shaping the industry. We’re here to assist with expert, personalized data.
Call +1 303 800 4326 or Send us a message for a personalized consultation.
Top 10 Trends in the Cardiotonic Agents Market
- Rising Prevalence of Heart Failure and CVDs
- Shift Toward Combination Therapies
- Precision/Personalised Medicine
- Novel Drug Delivery Systems
- Increasing Use of Biologics and Peptide-Based Drugs
- Integration Of AI In Drug Discovery
- Emergence Of RNA-Based Therapies
- Expansion Of Hospital-Based and Injectable Treatments
- Growth In Digital Health & Remote Monitoring
- Public-Private Partnerships and Increased R&D Investment
- Shift Toward Combination Therapies
Heart failure treatment has shifted from single-drug treatments to multiple medication approaches, which show better results for patients. The combined treatments result in fewer hospital stays and better survival outcomes when compared to single-drug treatment.
- Precision / Personalised Medicine
Doctors now use genetic information and biomarker data to create individualised treatment plans for patients requiring cardiotonic drugs. The method improves treatment efficiency while minimising side effects for medicines that have limited safety ranges.
- Novel Drug Delivery Systems
The development of new drug delivery systems leads to better treatment results through the use of injectable depot formulations and advanced delivery methods. The systems enable precise dosage management while minimising the potential for toxic effects.
- AI in Drug Discovery
Artificial intelligence accelerates drug development through its ability to shorten discovery periods while selecting better molecules. The system predicts toxicity and optimises compounds, which enables faster and more efficient development of cardiovascular drugs.
- RNA-Based & Advanced Therapies
New therapies using RNA and gene-targeting technologies are transforming cardiovascular treatment. The approaches deliver targeted treatment that works at the molecular level to enhance treatment results for heart failure and hypertension.
Empower your strategic planning
Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the anti-venom market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of The Cardiotonic Agents Market
Top 20 Companies Leading the Cardiotonic Agents Market
- Pfizer Inc.
- Novartis AG
- Sanofi S.A.
- Merck & Co., Inc.
- Bayer AG
- Bristol-Myers Squibb
- AstraZeneca
- Eli Lilly and Company
- Amgen Inc.
- GlaxoSmithKline (GSK)
- Boehringer Ingelheim
- Takeda Pharmaceutical Company
- Daiichi Sankyo
- Teva Pharmaceutical Industries
- CSL Limited
- United Therapeutics Corporation
- Aurobindo Pharma
- Sun Pharmaceutical Industries
- Dr. Reddy’s Laboratories
- Hikma Pharmaceuticals
- Pfizer Inc.
Headquarters: New York City, United States
Pfizer Inc. was established in 1849 and reported approximately $63.6 billion in revenue in 2024. The company offers various products, which include Eliquis as its cardiovascular medication, together with its vaccines and oncology and rare disease solutions. Pfizer operates in more than 125 countries, making it one of the most globally integrated pharmaceutical companies. The company's main achievement lies in its mRNA technology leadership, which enables the quick development of new treatment solutions.
- Novartis AG
Headquarters: Basel, Switzerland
Novartis AG, founded in 1996, generated around $50.3 billion in revenue in 2024. Its product portfolio includes major cardiovascular drugs like Entresto, as well as therapies in oncology, immunology, and generics. The company operates its business activities in more than 140 countries. The company dedicates its resources to developing new heart failure treatments, establishing itself as the top provider of advanced cardiotonic therapies.
- AstraZeneca
Headquarters: Cambridge, United Kingdom
AstraZeneca was established in 1999 and recorded approximately $54.0 billion in revenue in 2024. The company develops cardiovascular medications through its portfolio, which includes Farxiga and its cancer and respiratory and biologic drug treatments. AstraZeneca operates in more than 100 countries worldwide. The company establishes its main advantage through substantial funding of biopharmaceutical research and development and advanced treatments for heart disease.
- Merck & Co.
Headquarters: Rahway, United States
Merck & Co., Inc. was established in 1891 and achieved approximately $64.2 billion in revenue in 2024. The company offers a range of products that include cardiovascular treatments, Keytruda oncology medications, vaccines and diabetes management solutions. The company has a global presence in over 140 countries. The company maintains its position as a leading developer of major pharmaceuticals through its dedicated research and development efforts, which create a continuous flow of new products.
- Bayer AG
Headquarters: Leverkusen, Germany
Bayer AG was established in 1863 and generated approximately $19.6 billion in pharmaceutical revenue in 2024. The company markets Xarelto and other cardiovascular medications together with its consumer health products and crop science offerings. Bayer operates in more than 80 countries. The company maintains a major worldwide presence for its anticoagulant medications and cardiovascular treatments, which doctors commonly prescribe.
Are you ready to discover more about the Cardiotonic Agents Market?
The report provides an in-depth analysis of the leading companies operating in the global cardiotonic agents market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardised format that includes:
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of The Cardiotonic Agents Market
Company Profile
- Pfizer Inc.
- Business Overview
- Company Snapshot
- Products Overview
- Company Market Share Analysis
- Company Coverage Portfolio
- Financial Analysis
- Recent Developments
- Merger and Acquisitions
- SWOT Analysis
- Novartis AG
- Sanofi S.A.
- Merck & Co., Inc.
- Bayer AG
- Bristol-Myers Squibb
- AstraZeneca
- Eli Lilly and Company
- Amgen Inc.
- GlaxoSmithKline (GSK)
- Boehringer Ingelheim
- Takeda Pharmaceutical Company
- Daiichi Sankyo
- Teva Pharmaceutical Industries
- CSL Limited
- United Therapeutics Corporation
- Aurobindo Pharma
- Sun Pharmaceutical Industries
- Dr. Reddy’s Laboratories
- Hikma Pharmaceuticals
Conclusion
The global cardiotonic agents market size is expected to grow at a compound annual growth rate (CAGR) of 12.5%, from USD 2.9 billion in 2024 to USD 10.59 billion by 2035. Global market expansion is fuelled by the increasing number of heart failure cases, technological innovations in drugs and surgical methods, the shortage of effective methods to boost cardiac output and the growing number of cardiac surgery procedures and hospital-based cardiovascular care. North America held the majority of the market share by revenue for the cardiotonic agents market. This dominance is because the region experiences high rates of cardiovascular diseases, which require advanced healthcare facilities and increased healthcare spending. Asia-Pacific is projected to grow the fastest during the forecast period due to rising cardiovascular disease rates and the increasing need for efficient medical solutions.
Our Report
https://www.sphericalinsights.com/reports/italy-seed-treatment-market
https://www.sphericalinsights.com/reports/italy-compound-feed-market
https://www.sphericalinsights.com/reports/italy-data-center-market
https://www.sphericalinsights.com/reports/italy-food-colorants-market
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI. Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?